8-KFiled Aug 18, 8:00 PM ET
20/20 Biolabs Holds Annual Meeting; Charter Amendment Adjourned
$AIDX · 20/20 Biolabs, Inc.Research Summary
AI-generated summary of this SEC filing
20/20 Biolabs Holds Annual Meeting; Charter Amendment Adjourned
What Happened
- 20/20 Biolabs, Inc. (AIDX) held its annual meeting of stockholders on August 18, 2026 by webcast. As of the record date (June 22, 2026) there were 12,251,198 shares outstanding; 4,256,837 shares were represented, constituting a quorum.
- Stockholders elected six directors, ratified dbbmckennon as the independent registered public accounting firm for fiscal 2026, and approved the Company’s 2026 Equity Incentive Plan. Proposal 3 (a charter amendment) did not receive sufficient votes and was adjourned to September 16, 2026 at 10:00 a.m. ET to allow additional proxy solicitation; attendees can join the adjourned meeting via the same webinar portal used on Aug 18 (https://edge.media-server.com/mmc/go/AIDX2026AGM).
Key Details
- Outstanding shares and quorum: 12,251,198 shares outstanding; 4,256,837 shares present or by proxy.
- Directors elected (votes For / Withheld / Broker Non-Votes):
- Jonathan Cohen: 2,733,310 / 89,806 / 1,433,721
- John G. Compton, Ph.D.: 2,668,095 / 155,021 / 1,433,721
- Richard M. Cohen: 2,647,263 / 175,853 / 1,433,721
- Prasanth Reddy: 2,653,831 / 169,285 / 1,433,721
- John W. Rollins: 2,652,712 / 170,404 / 1,433,721
- Michael A. Ross, M.D.: 2,667,412 / 155,704 / 1,433,721
- Auditor ratification (Proposal 2): For 4,105,584; Against 132,421; Abstentions 18,832.
- 2026 Equity Incentive Plan (Proposal 4): For 2,183,335; Against 573,931; Abstentions 65,850; Broker Non-Votes 1,433,721.
- Adjournment approval to solicit additional proxies (Proposal 5): For 3,037,106; Against 1,132,166; Abstentions 87,565.
Why It Matters
- Governance: The board remains staffed with the six elected directors, which preserves continuity in leadership and oversight. Ratification of the auditor maintains the Company’s auditing arrangements for 2026.
- Capital/compensation: Approval of the 2026 Equity Incentive Plan enables the company to grant equity awards (possible dilution impact), which investors should monitor in future filings for share-count effects.
- Proxy dynamics: The failure to secure the charter amendment vote and the subsequent adjournment indicate the company will solicit additional proxies; the outcome on September 16, 2026 could affect corporate governance or charter provisions depending on the amendment’s content.